Real-life effectiveness evaluation of budesonide/formoterol (BF) DuoResp® Spiromax® for the management of asthma and COPD
![DuoResp Spiromax 320micrograms/dose / 9micrograms/dose dry powder inhaler ( Teva UK Ltd) 60 dose - RightBreathe DuoResp Spiromax 320micrograms/dose / 9micrograms/dose dry powder inhaler ( Teva UK Ltd) 60 dose - RightBreathe](https://www.rightbreathe.com/wp-content/uploads/2016/06/DuoResp-Spiromax-Dry-Powder-Inhaler-320.jpg)
DuoResp Spiromax 320micrograms/dose / 9micrograms/dose dry powder inhaler ( Teva UK Ltd) 60 dose - RightBreathe
![PDF) Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD PDF) Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD](https://i1.rgstatic.net/publication/346651654_Assessment_of_inhalation_errors_training_time_and_patient_preference_for_DuoRespR_SpiromaxR_and_SymbicortR_TurbuhalerR_in_patients_with_asthma_and_COPD/links/600eedb3a6fdccdcb87b76d1/largepreview.png)
PDF) Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD
Study report DuoResp Spiromax® for the daily routine of asthma and COPD treatment. Non-Interventional Study to Evaluate Patie
![Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study | BMC Pulmonary Medicine | Full Text Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study | BMC Pulmonary Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12890-015-0043-x/MediaObjects/12890_2015_43_Fig1_HTML.gif)